Alpha Tau Medical Ltd (DRTS) has released an update.
Alpha Tau Medical Ltd. has been accepted into the FDA’s Total Product Life Cycle Advisory Program, aiming to expedite the market access of its innovative Alpha DaRT therapy for recurrent glioblastoma multiforme. This development follows the company’s prior Breakthrough Device Designation, highlighting the potential of Alpha DaRT in addressing the critical needs of cancer patients. Investors might find this progress promising as it aligns with Alpha Tau’s strategy for commercialization and impact in the healthcare market.
For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.
